Skip to main content

Table 2 Part 2. Baseline clinical data of controlled study (n = 50)

From: Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial

Variables

Tranexamic acid (n = 24)

Placebo (n = 26)

P value

Demographic

   

   Age, years

66 (63–70)

67 (62–71)

0.91

   Male gender, number (percentage)

12 (50)

15 (57)

0.58

   Body mass index, kg/m2

28 (25.8–30.1)

28.1 (36.4–29.7)

0.98

   Parsonnet score

13.1 (11.8–15.5)

17.5 (13.7–21.3)

0.07

Comorbidity

   

Cardiopathy, number (percentage)

   

   Coronary

13 (54)

12 (46)

0.71

   Valve

9 (38)

10 (39)

0.68

   Mixed

2 (8)

4 (15)

0.44

Medical treatment

   

   Angiotensin-converting enzyme inhibitors, number (percentage)

11 (61)

7 (39)

0.16

   Calcium channel blockers, number (percentage)

6 (60)

4 (40)

0.39

Preoperative parameters

   

   Platelet count, × 103/mL

210 (186–234)

210 (186–239)

0.68

   Hemoglobin, g/dL

14.1 (13.5–14.6)

13.6 (12.8–14.4)

0.42

   International normalized ratio

1.08 (1.05–1.12)

1.09 (1.05–1.14)

0.97

   D-dimer, ng/mL

250 (166–333)

275 (215–325)

0.34

   Plasminogen activator inhibitor 1, ng/mL

34.2 (29–39.5)

35.2 (29.4–41.1)

0.95

Surgical data

   

   Cardiopulmonary bypass time, minutes

82 (71–94)

85 (74–96)

0.30

   Aortic clamping time, minutes

51 (44–58)

55 (47–62)

0.35

   Temperature after cardiopulmonary bypass, degrees Celsius

35.3 (34.9–35.6)

35.1 (34.7–35.3)

0.24

   Total heparin dose, UI/kg

430 (400–470)

420 (400–440)

0.69

   Total protamine dose, mg/kg

2.7 (2.5–3)

2.7 (2.6–2.9)

0.72

   Blood salvage device, mL

681 (605–756)

764 (694–833)

0.12

  1. Values are expressed as mean and 95% confidence interval or as frequency and percentage.